Loading clinical trials...

Active Not RecruitingPhase 1/2NCT06305767

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the ins...

Lead sponsor: Merck Sharp & Dohme LLC•10 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

NCT07217171 · Bladder Cancer, Squamous Cell Carcinoma of the Lung, and more

RECRUITINGPhase 2/3

Trop2-targeted immunoPET Imaging of Solid Tumors

NCT06851663 · Solid Tumor, Solid Carcinoma, and more

RECRUITINGPhase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179 · Non-muscle Invasive Bladder Cancer

RECRUITING

DESTINY-PANTUMOUR04

NCT07124000 · Adenocarcinoma (NOS), Anal Cancer, and more

RECRUITINGPhase 2

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

NCT06682728 · Urothelial Carcinoma, Muscle-invasive Bladder Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 13, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE1/PHASE2

Enrollment230

Start dateMar 2024

Last updatedJan 13, 2026

Condition

Bladder Cancer

Locations shown

UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104)

Los Angeles, California

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102)

Orlando, Florida

University of Chicago Medical Center ( Site 0109)

Chicago, Illinois

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2026Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions